Maria Mirotsou

USPTO Granted Patents = 9 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 2.3

ph-index = 2

Forward Citations = 19(Granted Patents)

Location History:

Dresden, DE (2009 - 2012)
Durham, NC (US) (2014 - 2022)

Company Filing History:

The Brigham and Women's Hospital, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2022

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11534464 - Direct reprogramming of cells to cardiac myocyte fate (2022-12-27),

2. 10695378 - Direct reprogramming of cells to cardiac myocyte fate (2020-06-30),

3. 10130637 - Inhibition of histone methyltransferase for cardiac reprogramming (2018-11-20),

4. 9987309 - Direct reprogramming of cells to cardiac myocyte fate (2018-06-05),

5. 9353168 - Method of reducing cell death by administering a paracrine factor derived from a mesenchymal stem cell (2016-05-31),

6. 9279012 - Method of reducing cell death by administering a nucleic acid encoding a paracrine factor of a mesenchymal stem cell (2016-03-08),

7. 8703710 - Method of reducing cell death by administering a paracrine factor of a mesenchymal stem cell (2014-04-22),

8. 8129344 - Method of reducing cell death by administering a Sfrp polypeptide (2012-03-06),

9. 7638128 - Method of enhancing cardiac tissue repair by administering a SFRP polypeptide (2009-12-29),

Title: Maria Mirotsou: Innovator in Cardiac Regeneration

Introduction

Maria Mirotsou is a prominent inventor based in Durham, NC (US), known for her groundbreaking work in cardiac regeneration. With a total of nine patents to her name, she has made significant contributions to the field of regenerative medicine, particularly in the conversion of cells into cardiomyocytes.

Latest Patents

Among her latest patents is a method for promoting the conversion of cells into cardiomyocytic tissue. This innovative approach involves contacting fibrotic tissue, such as scar tissue, with a microRNA oligonucleotide or a combination of microRNA oligonucleotides. The methods developed by Mirotsou lead to the direct reprogramming of fibroblasts into cardiomyocytes or cardiomyoblasts, showcasing her expertise in cellular reprogramming.

Career Highlights

Maria has worked with esteemed institutions, including Duke University and Brigham and Women's Hospital, Inc. Her research has been pivotal in advancing the understanding of cardiac tissue regeneration and has opened new avenues for therapeutic interventions in heart diseases.

Collaborations

Throughout her career, Maria has collaborated with notable professionals in her field, including Victor J. Dzau and Tilanthi Jayawardena. These collaborations have further enriched her research and contributed to the success of her innovative projects.

Conclusion

Maria Mirotsou stands out as a leading inventor in the realm of cardiac regeneration, with her innovative methods and collaborative efforts paving the way for future advancements in regenerative medicine. Her work continues to inspire and influence the field significantly.

This text is generated by artificial intelligence and may not be accurate.